Coronary Artery Lesions
The purpose of this study is to check the safety of 3-month dual antiplatelet therapy (DAPT) in patients at high risk of bleeding (HBR) with the approved XIENCE family of coronary drug-eluting stents.
This research study is led by Dr. Gregory Giugliano.
Contact: Annette Scarnici, RN, CCRC, 413-794-9076
June 01, 2017
Baystate Medical Center, 759 Chestnut Street, Springfield, MA
- At least 18 years of age
- History of major bleeding
- History of stroke